ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obinutuzumab

Also written as “Obinutuzumab”, “Obinutuzumab, naptumomab estafenatox and durvalumab” and “obinutuzumab (RO5072759)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lupus Nephritis · Lupus Erythematosus, Systemic, led by 2 companies.

Drug pageObinutuzumab: every studyAll 172 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 24, 201935 company-led studies, 7 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche325 open or runningphase 4since Jan 24, 2019Aug 16, 2007Dec 28, 2026phase 2 · NCT04077723
AbbVieits history only32 open or runningphase 3since May 20, 2024May 19, 2021Nov 2026phase 2 · NCT04895436

Also a collaborator on its studies: AstraZeneca and Roche Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Aug 16, 2007.

  1. Dec 16, 2014Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02320487 · 102 enrolled · United States
  2. Sep 14, 2015Phase 2 study in Lupus NephritisNCT02550652 · 126 enrolled · United States, Argentina, Brazil and more
  3. Oct 23, 2015Phase 1 study in Kidney Failure, ChronicNCT02586051 · 24 enrolled · United States
  4. Nov 3, 2015Phase 2 study in RecurrenceNCT02600897 · 114 enrolled · United States, Spain, United Kingdom
  5. Dec 1, 2015Phase 2 study in Lymphoma, Non-HodgkinNCT02624986 · 25 enrolled · United States, Australia, Germany and more
  6. Jan 24, 2019Phase 4 study in Advanced Follicular LymphomaNCT03817853 · 114 enrolled · United States, Brazil, Germany and more
  7. Mar 6, 2019Phase 1 study in Colorectal NeoplasmsNCT03866239 · 47 enrolled · United States, Denmark, France and more
  8. Aug 9, 2019Phase 2 study in Lymphoma, Non-HodgkinNCT04077723 · 498 enrolled · United States, Australia, Belgium and more
  9. Jan 7, 2020Phase 3 study in Lupus NephritisNCT04221477 · 271 enrolled · United States, Argentina, Brazil and more
  10. Feb 25, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04285567 · 166 enrolled · United States, Australia, France and more
  11. Oct 27, 2020Phase 3 study in Primary Membranous NephropathyNCT04629248 · 142 enrolled · United States, Argentina, Brazil and more
  12. Jul 7, 2021Phase 3 study in Lupus Erythematosus, SystemicNCT04963296 · 303 enrolled · United States, Argentina, Brazil and more
  13. Sep 1, 2021Phase 2 study in Lupus NephritisNCT05039619 · 40 planned · United States, Brazil, Canada and more
  14. Nov 4, 2022Phase 3 study in Nephrotic SyndromeNCT05627557 · 85 enrolled · United States, Belgium, Brazil and more
  15. Jul 19, 2026Named obinutuzumabINNProposed as its International Nonproprietary Name in WHO's List 135

Ahead

  1. Dec 28, 2026Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT04077723
  2. Jun 15, 2028Primary completion: phase 2 study in Lupus NephritisNCT05039619

TargetBeta

MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 32 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05627557Nephrotic Syndrome · United States, Belgium, Brazil and more3CompletedSep 4, 202585
NCT05039619Lupus Nephritis · United States, Brazil, Canada and more2RecruitingJun 15, 202840
NCT04963296Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3Active, not recruitingSep 15, 2025303
NCT04629248Primary Membranous Nephropathy · United States, Argentina, Brazil and more3Active, not recruitingDec 22, 2025142
NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3CompletedMar 19, 2024166
NCT04221477Lupus Nephritis · United States, Argentina, Brazil and more3Active, not recruitingAug 15, 2024271
NCT04077723Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more2Active, not recruitingDec 28, 2026498
NCT03866239Colorectal Neoplasms · United States, Denmark, France and more1TerminatedMar 13, 202447
NCT03817853Advanced Follicular Lymphoma · United States, Brazil, Germany and more4CompletedAug 4, 2020114
NCT02624986Lymphoma, Non-Hodgkin · United States, Australia, Germany and more2TerminatedMay 20, 201925
NCT02600897Recurrence · United States, Spain, United Kingdom2CompletedDec 15, 2021114
NCT02586051Kidney Failure, Chronic · United States1CompletedNov 26, 201824
NCT02550652Lupus Nephritis · United States, Argentina, Brazil and more2CompletedJan 15, 2019126
NCT02320487Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedNov 7, 2016102
NCT02071225Leukemia, Lymphocytic, Chronic, B-Cell · Spain2CompletedNov 19, 201872
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedJun 28, 2017267
NCT02053610Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedAug 31, 2013787
NCT01998880Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedAug 1, 2012787
NCT01905943Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Belgium, Bosnia and Herzegovina and more3CompletedDec 29, 2016979
NCT01868893Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedJan 201420
NCT01691898Lymphoma, Follicular · United States, Canada, France and more2CompletedMar 8, 2017231
NCT01685892Leukemia, Lymphocytic, Chronic, B-Cell · United States, United Kingdom1CompletedMay 21, 201882
NCT01680991Leukemia, Lymphoid · China1CompletedDec 201448
NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany1CompletedAug 17, 201884
NCT01414855Lymphoma, B-Cell · United States2CompletedDec 31, 2013100
NCT01414205Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedMar 31, 201380
NCT01332968Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more3CompletedFeb 1, 20161,401
NCT01287741Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more3TerminatedApr 29, 20161,418
NCT01059630Lymphoma, Non-Hodgkin · United States, Austria, Belgium and more3CompletedSep 30, 2014413
NCT01010061Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedJul 1, 2012787
NCT00576758Lymphoma, Non-Hodgkin · United States, Argentina, Austria and more2CompletedSep 2011175
NCT00517530Lymphoma · France, Germany2CompletedNov 2013134

How it is read

Names in the registry

  • “Obinutuzumab”, 35 entries
  • “obinutuzumab”, 5 entries
  • “Obinutuzumab, naptumomab estafenatox and durvalumab”, 1 entry
  • “obinutuzumab (RO5072759)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.